Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 17, 2021

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2027

Conditions
HypertensionCardiovascular Diseases
Interventions
DRUG

Ascorbic acid solution (American Regent Laboratories Inc.)

"Ascorbic acid solution (American Regent Laboratories Inc.) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min."

DRUG

Saline

Placebo (saline) will be administered

Trial Locations (1)

66160

RECRUITING

University of Kansas Medical Center, Kansas City

All Listed Sponsors
lead

University of Kansas Medical Center

OTHER